With Remix Therapeutics joining forces with Roche and Daiichi Sankyo partnering with Depixus, there has been many valuable collaborations entering the RNA-targeting field accelerating efficacious and selective small molecules targeting RNA directly, RNA-binding proteins and RNA/protein complexes.

Hence, as the go-to meeting for the RNA-targeting small molecule the community, the 7th Annual RNA-Targeted Drug Discovery and Development Summit returns to Boston this December. Increase your knowledge of RNA tertiary structures, delve into innovative preclinical modelling strategies and identify optimal chemical features for advancing specific, efficacious and safe small molecules.

Unite with 100+ RNA Science, Medicinal Chemistry, Structural Biology and Biophysics experts from the likes of AstraZeneca, Sanofi, Novartis, PTC Therapeutics, ReviR Therapeutics, Rgenta Therapeutics, Accent Therapeutics and more at the most comprehensive and definitive event for the community, the 7th RNA-Targeted Drug Discovery and Development Summit, to accomplish faster and smoother translation of RNA targeted therapies towards the clinic.

URLs:
Tickets: https://go.evvnt.com/2583808-2?pid=91
Brochure: https://go.evvnt.com/2583808-3?pid=91

Prices:
Industry Pricing - Conference + Focus Day OR Workshop Day: USD 4197.00,
Industry Pricing - Conference Only: USD 2999.00,
Academic Pricing - Conference + Focus Day OR Workshop Day: USD 3597.00,
Academic Pricing - Conference Only: USD 2599.00,
Service Provider Pricing - Conference + Focus Day OR Workshop Day: USD 5097.00,
Service Provider Pricing - Conference Only: USD 3699.00

Speakers: Alisha Jones, Assistant Professor, Chemistry, New York University, Amanda Hargrove, Professor, Chemistry, University of Toronto, Anu Bhattacharyya, Vice President, Splicing Drug Development, PTC Therapeutics, Bertrand Adanve, Founder and Chief Executive Officer, Genetic Leap, Chris Burge, Professor, Massachusetts Institute of Technology, Chris Yates, Executive Director and Head, Medicinal Chemistry, Rgenta Therapeutics, Chuhern Hwang, Co-Founder and Head, Drug Discovery, Wayfinder Biosciences, David Brower, Chief Business Officer, Accent Therapeutics, Domi Stickens, Vice President, Discovery Biology and Translational Sciences, Arrakis Therapeutics, Dominic Reynolds. Chief Scientific Officer. Remix Therapeutics, Hashim Al-Hashimi, Co-founder and Platform Architect, Base4 Biotechnology, John Schneekloth, Senior Investigator, National Cancer Institute, Joon Lee, Associate Scientific Director, Biogen, Joy Ghosh, Managing Director, Abingworth, Kenneth Duncan, Senior Vice President, Chemistry, Accent Therapeutics, Kerstin Effenberger, Principal Scientist, Discovery Splicing, PTC Therapeutics, Kevin Weeks, Kenan Distinguished Professor, Chemistry, University of North Carolina at Chapel Hill, Manisha Sinha, Senior Director, Translational Biology, Expansion Therapeutics, Matt Friedersdorf, Associate Director, Translational Medicine, Ribometrix, Paul August, Chief Scientific Officer, ReviR Therapeutics, Perla Breccia, Senior Director, Chemistry, AstraZeneca, Peter Connolly, Vice President, Structural Biology and Biophysics, Expansion Therapeutics, Rhona Cox, Director, Medicinal Chemistry, AstraZeneca, Shunnichi Kashida, Co-Founder, Representative Director, President and Chief Executive Officer, xFOREST Therapeutics, Steve Lianoglou, Director, Translational Genomics, ReviR Therapeutics, Tom Chappie, Research Fellow, Pfizer, Vipender Singh, Senior Principal Scientist and Project Team Leader, Novartis - Biomedical Research, Yang Zheng, Head of Business Development, Base4 Biotechnology, Yann Foricher, Head of Small Molecules Medicinal Chemistry, Sanofi